*Rx* Federal law restricts this drug to use by or on the order of a licensed veterinarian. For intramuscular injection in swine only. Inject intramuscularly as a single dose in the neck at a dosage of 2.5 mg/kg ( 1 ml/22lb) body weight. Do not inject more than 4ml per injection site.
DRAXXIN 25 offers one-dose convenience and ease of administration so you can be sure your small pigs receive the treatment for swine respiratory disease (SRD) they need.
Important Safety Information for Swine:The pre-slaughter withdrawal time for DRAXXIN in swine is five days. DRAXXIN should not be used in animals known to be hypersensitive to the product.
DRAXXIN 25 Injectable Solution is indicated for the treatment of swine respiratory disease (SRD) associated with Actinobacillus pleuropneumoniae, Pasteurella multocida, Bordetella bronchiseptica, Haemophilus parasuis, and Mycoplasma hyopneumoniae; and for the control of SRD associated with Actinobacillus pleuropneumoniae, Pasteurella multocida, and Mycoplasma hyopneumoniae in groups of pigs where SRD has been diagnosed.
DRAXXIN 25 Injectable Solution is a ready-to-use sterile parenteral preparation containing tulathromycin, a semi-synthetic macrolide antibiotic of the subclass triamilide. Each mL of DRAXXIN 25 contains 25 mg of tulathromycin as the free base in a 50% propylene glycol vehicle, monothioglycerol (5 mg/mL), citric acid (4.8 mg/mL) with hydrochloric acid and sodium hydroxide added to adjust pH.
|
Animal Weight (Pounds) |
Dose Volume (mL) |
|---|---|
| 4 | 0.2 |
| 10 | 0.5 |
| 15 | 0.7 |
| 20 | 0.9 |
| 22 | 1.0 |
| 25 | 1.1 |
| 30 | 1.4 |
| 50 | 2.3 |
| 70 | 3.2 |
| 90 | 4.0 |
CONTRAINDICATIONS
The use of DRAXXIN 25 Injectable Solution is contraindicated in animals previously found to be hypersensitive to the drug.
WARNINGS
FOR USE IN ANIMALS ONLY.
NOT FOR HUMAN USE.
KEEP OUT OF REACH OF CHILDREN.
NOT FOR USE IN CHICKENS OR TURKEYS.
CLINICAL PHARMACOLOGY
At physiological pH, tulathromycin (a weak base) is approximately 50 times more soluble in hydrophilic than hydrophobic media. This solubility profile is consistent with the extracellular pathogen activity typically associated with the macrolides.1 Markedly higher tulathromycin concentrations are observed in the lungs as compared to the plasma. The extent to which lung concentrations represent free (active) drug was not examined. Therefore, the clinical relevance of these elevated lung concentrations is undetermined.
Although the relationship between tulathromycin and the characteristics of its antimicrobial effects has not been characterized, as a class, macrolides tend to be primarily bacteriostatic, but may be bactericidal against some pathogens. 2 They also tend to exhibit concentration independent killing; the rate of bacterial eradication does not change once serum drug concentrations reach 2 to 3 times the minimum inhibitory concentration (MIC) of the targeted pathogen. Under these conditions, the time that serum concentrations remain above the MIC becomes the major determinant of antimicrobial activity. Macrolides also exhibit a post-antibiotic effect (PAE), the duration of which tends to be both drug and pathogen dependent. In general, by increasing the macrolide concentration and the exposure time, the PAE will increase to some maximal duration. Of the two variables, concentration and exposure time, drug concentration tends to be the most powerful determinant of the duration of PAE.
Tulathromycin is eliminated from the body primarily unchanged via biliary excretion.